Indaptus Therapeutics, Inc. has received Clinical Trial Authorization from Health Canada to expand its U.S. clinical trial of Decoy20, a treatment for cancer and viral infections, into Canadian sites.
Regulatory changes and damages risks are prompting Canadian firms and clients to opt for settlements in generic and biosimilar cases Canadian practitioners say they are increasingly helping clients ...
A phase III randomized trial of radiotherapy optimization for low-risk HER2-positive breast cancer (HERO): NRG-BR008. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results